SCHEMBL20512424

SCHEMBL20512424

Cn1cnc2cc(Br)c(F)c(F)c21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.42
C1S P09871 1/20 0.32
DPP8 Q6V1X1 2/20 0.31
PIK3CD O00329 1/20 0.30
POLB P06746 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
CNR1 P21554 1/20 0.30
ACHE P22303 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA2B P29275 1/20 0.30
ADORA1 P30542 1/20 0.30
NTSR1 P30989 1/20 0.30
MC3R P41968 1/20 0.30
NOTUM Q6P988 1/20 0.30
SIRT3 Q9NTG7 1/20 0.30
GDA Q9Y2T3 1/20 0.30
NR2E1 Q9Y466 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21187469 0.81 DPP4 (0.42) DPP4C1SDPP8PIK3CDPOLB
SCHEMBL17563255 0.79 DPP4 (0.36) DPP4DPP8PIK3CDPOLBADORA3
SCHEMBL13137285 0.78 DPP4 (0.41) DPP4DPP8
SCHEMBL29669299 0.78 DPP4 (0.35) DPP4DPP8PIK3CDPOLBADORA3
SCHEMBL24463371 0.78 DPP4 (0.35) DPP4DPP8PIK3CDPOLBADORA3
SCHEMBL26790794 0.75 DPP4 (0.35) DPP4ADORA2B
SCHEMBL17694882 0.75 DPP4 (0.34) DPP4POLB
SCHEMBL20698154 0.74 PRPS1 (0.41) DPP4C1SDPP8PIK3CDPOLB
SCHEMBL13676391 0.74 DPP4 (0.38) DPP4DPP8PIK3CDPOLBADORA3
SCHEMBL23519683 0.74 DPP4 (0.36) DPP4DPP8ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
CN-112203653-B Compounds for the treatment of huntington's disease PTC医疗公司 2024-08-16 CN disclosed
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2023-10-19 US disclosed
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2023-10-19 US disclosed
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2023-10-19 US disclosed
US-11780839-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11780839-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11780839-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
CN-110740991-B Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2023-07-04 CN disclosed
EP-3632443-B1 ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2023-06-07 EP disclosed
US-10723742-B2 Biphenyl compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-07-28 US disclosed
US-20200190175-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-06-18 US disclosed
EP-3632443-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
EP-3632897-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
EP-3633380-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
CN-110740991-A Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2020-01-31 CN disclosed
WO-2019191229-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2019-10-03 WO disclosed
WO-2019191229-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2019-10-03 WO disclosed
US-20180354960-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-12-13 US disclosed
EP-3381896-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2018-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723742-B2 Biphenyl compound or salt thereof KDM1B, BMI1, HDAC1 DPP4 2612/4885C1S 4702/4885DPP8 2337/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B DPP4 1963/4885C1S 4865/4885DPP8 904/4885
US-20200190175-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 INMT, CARM1, KDM1B DPP4 1963/4885C1S 4865/4885DPP8 904/4885
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, HDAC6 DPP4 2606/4885C1S 3582/4885DPP8 3189/4885
US-20180354960-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, HDAC1, DOT1L DPP4 3091/4885C1S 4580/4885DPP8 2727/4885
US-11780839-B2 Compounds for treating Huntington's disease HTT, HYPK, HDAC6 DPP4 2606/4885C1S 3582/4885DPP8 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.